Let’s Talk Medtech

EY's Jim Welch stops by to discuss the EY Pulse of the Industry report and to discuss the state of M&A in medtech.

Dr. Jim Mault, BioIntellisense CEO, breaks down the rise of remote patient monitoring and explains why it’s time to drop the term. He also speaks about his time at Microsoft and Qualcomm.

Guardant Health's Co-Founder and CEO Helmy Eltoukhy discusses the company's growth and sheds light on the rapidly changing field of liquid biopsy.

BIOMEDevice Boston is fully loaded in 2022! Adrienne Zepeda, Group Event Director at Informa Markets - Engineering, gives us the scoop on why this is the show's biggest year ever!

The Massachusetts Medical Device Industry Council (MassMEDIC) has launched the Why Medtech campaign to build awareness of the medical device industry. MassMEDIC's Brian Johnson and Rachel Robinson joins us for this episode to discuss how people can take part in this campaign and why everyone has medtech story.

One of the current trends in the medtech industry involves companies expanding digital solutions. While digital innovation can be slow to progress in regulated industries like healthcare, GE Healthcare is changing the game with Edison Digital Health Platform, a vendor-agnostic hosting and data aggregation platform with an integrated artificial intelligence (AI) engine.  

Vignesh Shetty, Senior VP & General Manager of Edison AI And Platform at GE Healthcare, discusses why the digital platform is a difference maker.

Sometimes as a company grows and matures, the corporate identity it started out needs to change. Memic Innovative Surgery is the perfect example as the company has changed its name to Momentis Surgical. In addition the company has also changed the name of its technology from the Hominis Surgical System to Anovo Surgical.

DVir Cohen, CEO of Momentis Surgical, discusses the name change and how the Anovo Surgical system stands out in the surgical robotics space.

Ruby Gadelrab, CEO and founder of MDisrupt, stops by Let’s Talk Medtech for a candid conversation about digital health, diversity, and working to create an atmosphere of inclusion in the space. Plus, she shares her professional experience.

It's no secret that Dexcom is on the rise. From commercials during the Super Bowl, to blockbuster products on the horizon, the company is reaching a new height of popularity in the continuous glucose monitoring space.

Kevin Sayer, Dexcom CEO, talks about the company's new position the space and all the hype surrounding the upcoming G7 CGM sensor. He also gives his thoughts on where CGM technology is headed in this incredible, can't miss conversation.

It's hard to believe it's been more than 10 years ago since FitBit pioneered the fitness wearables market. As the technology has advanced, the lines between what is a consumer wellness device and what is a medical-grade wearable have begun to blur, with a number of companies sitting at the intersection of consumer wellness and medical-grade wearables. One such company is Movano.

John Mastrototaro, CEO at Movano, joins the latest episode of Let's Talk Medtech to discuss that intersection of consumer and medical-grade wearables, and why he joined Movano. The Pleasanton, CA-based company is creating consumer products designed to deliver medical-grade data. Founded in 2018, the company recently announced that its first product will be a fitness ring designed specifically for women that measures heart rate, heart rate variability, sleep, respiration, temperature, blood oxygen, steps, and calories.

Movano is currently conducting clinical trials with its radio frequency-enabled technology and developing algorithms to add medical data, including non-invasive glucose monitoring and cuffless blood pressure, to its core product in the future. The company plans to execute accuracy studies to pursue FDA clearances on its vital signs monitoring capabilities including heart rate, SpO2, and respiration rate.

The Movano Ring is expected to be available through a beta release in the second half of 2022.